Provided by Tiger Trade Technology Pte. Ltd.

Maze Therapeutics

26.20
-0.3350-1.26%
Volume:141.52K
Turnover:3.76M
Market Cap:1.45B
PE:-10.41
High:27.44
Open:26.49
Low:26.00
Close:26.53
52wk High:53.65
52wk Low:14.16
Shares:55.25M
Float Shares:37.25M
Volume Ratio:0.72
T/O Rate:0.38%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.5172
EPS(LYR):-3.0510
ROE:-37.35%
ROA:-21.79%
PB:3.19
PE(LYR):-8.59

Loading ...

Maze Therapeutics announces annual shareholder meeting

Reuters
·
Apr 29

Wedbush Cuts Price Target on Maze Therapeutics to $48 From $58, Keeps Outperform Rating

MT Newswires Live
·
Apr 23

Maze Therapeutics prices $150 million equity offering

TIPRANKS
·
Apr 23

BUZZ-U.S. STOCKS ON THE MOVE-Tesla, AT&T, Yesway

Reuters
·
Apr 23

BUZZ-Maze Therapeutics jumps on $150 mln share offering for kidney disease drugs

Reuters
·
Apr 23

Maze Therapeutics publishes corporate presentation on genetics-driven kidney and metabolic disease pipeline

Reuters
·
Apr 22

BRIEF-Maze Therapeutics Announces $150 Million Registered Offering

Reuters
·
Apr 22

Maze Therapeutics prices $150 million follow-on stock offering at $23.5 per share

Reuters
·
Apr 22

Maze Therapeutics Inc - Prices 5,540,000 Shares at $23.50 per Share

THOMSON REUTERS
·
Apr 22

Maze Therapeutics Is Maintained at Buy by Truist Securities

Dow Jones
·
Apr 14

Maze Therapeutics price target lowered to $64 from $68 at Truist

TIPRANKS
·
Apr 14

Analysts Offer Insights on Healthcare Companies: Travere Therapeutics (TVTX), Immuneering (IMRX) and Maze Therapeutics, Inc. (MAZE)

TIPRANKS
·
Apr 14

Assessing Maze Therapeutics (MAZE) Valuation After Strong One Year Return And Recent Pullbacks

Simply Wall St.
·
Apr 09

Wall Street Analysts Are Bullish on Top Healthcare Picks

TIPRANKS
·
Apr 07

Maze Therapeutics President R&D, CMO Harold Bernstein disposes shares worth $0.4 million

Reuters
·
Apr 03

Maze SVP Finance Amy Bachrodt disposes Maze Therapeutics shares worth $0.1 million

Reuters
·
Apr 03

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Apr 02

Maze Therapeutics CSBO Atul Dandekar disposes of common shares worth $0.2 million

Reuters
·
Apr 02

Maze Therapeutics director Neil Kumar files initial beneficial ownership statement

Reuters
·
Apr 01

Maze Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
Apr 01